% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pomykala:274335,
      author       = {K. L. Pomykala and B. A. Hadaschik and O. Sartor and S.
                      Gillessen and C. J. Sweeney and T. Maughan and M. S. Hofman
                      and M. Herrmann$^*$},
      title        = {{N}ext {G}eneration {R}adiotheranostics {P}romoting
                      {P}recision {M}edicine.},
      journal      = {Annals of oncology},
      volume       = {34},
      number       = {6},
      issn         = {0923-7534},
      address      = {Amsterdam [u.a.},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-00541},
      pages        = {507-519},
      year         = {2023},
      note         = {2023 Jun;34(6):507-519},
      abstract     = {Radiotheranostics is a field of rapid growth with some
                      approved treatments including 131I for thyroid cancer, 223Ra
                      for osseous metastases, 177Lu-Dotatate for neuroendocrine
                      tumors, and 177Lu-PSMA for prostate cancer, and several more
                      under investigation. In this review, we will cover the
                      fundamentals of radiotheranostics, the key clinical studies
                      that have led to current success, future developments with
                      new targets, radionuclides and platforms, challenges with
                      logistics and reimbursement and, lastly, forthcoming
                      considerations regarding dosimetry, identifying the right
                      line of therapy, artificial intelligence and more.},
      subtyp        = {Review Article},
      keywords     = {(177)Lu-Dotatate (Other) / (177)Lu-PSMA (Other) /
                      endoradiotherapy (Other) / positron emission tomography
                      (Other) / radiotheranostics (Other) / targeted radioligand
                      therapy (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36924989},
      doi          = {10.1016/j.annonc.2023.03.001},
      url          = {https://inrepo02.dkfz.de/record/274335},
}